Knockdown of BDNF-AS1 in HeLa cells by Lincode SMARTpool and four siRNAs. All siRNAs were used at 25 nM, normalized and remaining lncRNA transcripts were detected with Solaris (sold under the Thermo Scientific brand) qPCR lncRNA Expression Assays and normalized to Non-targeting Control siRNA. Viability was assessed by resazurin assay.
Knockdown of CDKN2B-AS1 in hNDF cells by Lincode SMARTpool and four siRNAs. All siRNAs were used at 25 nM, normalized and remaining lncRNA transcripts were detected with Solaris qPCR lncRNA Expression Assays and normalized to Non-targeting Control siRNA. Viability was assessed by resazurin assay.
Robust qPCR assays are necessary for accurate determination of lncRNA expression levels.
lncRNAs demonstrate lower and more variable expression than protein-coding genes. It is therefore highly recommend to determine lncRNA expression levels in your cells prior to knockdown experiments. Solaris qPCR expression assays are designed for sensitive detection of lncRNA and demonstrate high sensitivity and reproducibility.
50 ng of total RNA was converted into cDNA using the Maxima First Strand cDNA Synthesis Kit (#K1641). Gene expression levels were evaluated with Solaris qPCR assays. Cyclophilin B (PPIB) was used as a reference for typical mRNA expression. Standard RT-PCR cycling conditions resulted in initial Cq values ranging from 22 (PPIB in 293T cells) to 36 (BDNF-AS1 in HeLa cells). MLK7-AS1 lncRNA expression was not detectable in any of the cell lines tested. Cell lines include HeLa, HEK293T, Human Neonatal Dermal Fibroblast (hNDF).
Lincode siRNA effectively knocks down BDNF-AS1 lncRNA, but not the protein-coding transcript BDNF that is antisense to the lncRNA target. This indicates strand specificity of Lincode siRNAs and effectiveness of ON TARGETplus modifications. siRNAs were applied at the indicated concentrations to hNDF cells. BDNF-AS1 and BDNF transcripts were detected with Solaris qPCR Expression Assays and normalized to Non-targeting control siRNA. Viability was assessed by resazurin assay and normalized to Untreated.
Genomewide expression analysis demonstrates improved specificity of Lincode siRNA
To detect subtle phenotypic changes that may arise from lncRNA knockdown, it is essential to incorporate strategies to prevent the off-targeting of protein-coding genes. Lincode siRNA reagents are synthesized with proprietary dual-strand modifications known as the ON-TARGETplus modification pattern which has been proven to reduce off-targets arising from microRNA-like activity of the antisense seed region of the siRNA.
Two different siRNAs targeting the same lncRNA were synthesized with modifications that (a) block the sense strand only or (b) the ON-TARGETplus modification pattern which blocks the sense strand and includes an antisense strand seed region modification. While the target lncRNA was effectively silenced by all four siRNAs (arrows), the siRNAs synthesized with the ON-TARGETplus modifications demonstrated greatly reduced off-targets.
Agilent™ G3 Human Gene Expression Microarray™ HeLa 12K, harvest 24 hrs post transfection, 100 nM siRNA, Analysis: >2 fold down regulated, pval <0.05, and non-siRNA-specific effects filtered out.
Lincode siRNAs are modified with a proprietary dual-strand modification that improves siRNA functionality. Additionally, off-targets are reduced due to:
- Inactivation of passenger strand activity; driving preferential loading of the guide strand into RISC
- Novel seed region modifications for disruption of microRNA-like off-targets